Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA/Industry Dispute On Hypogonadism Drug Efficacy Endpoints To Get Panel Review

Executive Summary

Clinical trials should go beyond merely demonstrating maintenance of spermatogenesis, US FDA says, but drug developers assert an increase in serum testosterone levels and/or improvement or maintenance of sperm concentration are appropriate clinical measures to support approval.


Related Content

Hypogonadism Trial Designs: FDA Panel Favors Symptom Assessments, Fertility Measures
Recent And Upcoming FDA Advisory Committees
Repros Therapeutics Needs New Pivotal Trial For Low T Drug Enclomiphene
Repros At A Loss After FDA Abruptly Cancels Enclomiphene Panel Review
‘Low-T’ Drugs Need Randomized CV Safety Trials, FDA Panel Says


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts